Background: Real-world data on tyrosine kinase inhibitor (TKI) use in chronic myeloid leukemia (CML) from the Middle East remain limited. We evaluated treatment patterns, molecular responses, treatment-free remission (TFR), and safety among Omani patients with chronic-phase CML. Methods: In this retrospective single-center study, adult patients (≥18 years) with chronic-phase CML treated with TKIs between January 2008 and September 2024 were included. Demographics, Sokal risk, treatment lines, molecular responses, TFR, and adverse drug reactions (ADRs) were analyzed. Results: Among 112 patients (mean age 43.7 ± 15.4 years), 45% had low Sokal risk, 43% intermediate, and 12% high risk. Imatinib was first-line therapy in 88.4%, achieving major molecular response (MMR) in 51%, with a median time to MMR of 21 months. In contrast, second-line TKIs demonstrated higher efficacy, with MMR rates of 79.2% for nilotinib and 54.4% for dasatinib, and shorter time to response (12 vs 23.2 months, respectively). Successful TFR was maintained in 17% of imatinib-treated patients after two years and in 83.3% of second-line patients after 36 months. ADRs were mainly gastrointestinal (28.5%), musculoskeletal (28.0%), dermatologic (20.8%), and hematologic (8.7%). Grade 3–4 events occurred in 5%, leading to TKI switching. Discontinuations were primarily due to loss of response, ADRs, or planned TFR. Conclusion: In this real-world cohort, first-line imatinib provided acceptable but slower and less frequent molecular responses compared with second-generation TKIs. Higher TFR maintenance rates were observed with second-generation TKIs, although interpretation is limited by small patient numbers. These findings support a response-guided, risk-adapted approach to TKI selection and highlight the need to expand access to second-generation TKIs to optimize long-term outcomes in CML.